X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-06-04 | VREO | Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% | P - Purchase | $0.41 | +26,000 | 111,226,655 | 0% | +$10,530 | |||||
2025-06-06 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $6.76 | -17,795 | 491,246 | -3% | -$120,294 | ||||||
2025-06-06 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $6.76 | -50,676 | 1,303,761 | -4% | -$342,570 | ||||||
| D | 2025-06-05 | XENE | Xenon Pharmaceuticals Inc. | Gannon Steven | Dir | S - Sale+OE | $30.48 | -3 | 7,141 | 0% | -$91 | |||||
2025-06-06 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | SVP, GC | S - Sale | $6.76 | -10,470 | 378,245 | -3% | -$70,777 | ||||||
| M | 2025-06-04 | ROIV | Roivant Sciences Ltd. | Ramaswamy Vivek | 10% | S - Sale | $11.30 | -748,230 | 51,784,238 | -1% | -$8,454,808 | |||||
| M | 2025-06-04 | ORGO | Organogenesis Holdings Inc. | Freedman Lori | Chief Admin., Legal Officer | P - Purchase | $2.88 | +252,264 | 846,459 | +42% | +$725,290 | |||||
| M | 2025-06-04 | ASBP | Aspire Biopharma Holdings, Inc. | Fell Donald G. | Dir | P - Purchase | $0.39 | +20,000 | 20,000 | New | +$7,800 | |||||
| D | 2025-06-04 | IMUX | Immunic, Inc. | Vitt Daniel | CEO, Dir | P - Purchase | $0.77 | +15,000 | 391,877 | +4% | +$11,550 | |||||
2025-06-05 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale | $73.50 | -1,879 | 67,718 | -3% | -$138,107 | ||||||
2025-06-05 | KRON | Kronos Bio, Inc. | Knobelman Deborah | Pres, Interim CEO | S - Sale | $0.87 | -24,838 | 139,422 | -15% | -$21,554 | ||||||
| M | 2025-06-04 | TYRA | Tyra Biosciences, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $9.70 | +1,211,198 | 11,848,488 | +11% | +$11,751,304 | |||||
2025-06-04 | STOK | Stoke Therapeutics, Inc. | Skorpios Trust | 10% | S - Sale | $10.20 | -3,000,000 | 3,906,181 | -43% | -$30,600,000 | ||||||
2025-06-05 | DYN | Dyne Therapeutics, Inc. | Cox John | CEO, Pres | S - Sale | $13.35 | -4,060 | 174,179 | -2% | -$54,201 | ||||||
2025-06-05 | DYN | Dyne Therapeutics, Inc. | Kerr Douglas | Chief Medical Officer | S - Sale | $13.35 | -1,342 | 92,815 | -1% | -$17,916 | ||||||
2025-06-05 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Officer | S - Sale | $13.35 | -146 | 95,911 | 0% | -$1,949 | ||||||
| M | 2025-06-04 | ARQT | Arcutis Biotherapeutics, Inc. | Heron Patrick J | Dir | P - Purchase | $13.34 | +2,268 | 8,852,607 | 0% | +$30,247 | |||||
| M | 2025-05-01 | CPIX | Cumberland Pharmaceuticals Inc | Krogulski Kenneth | Dir | P - Purchase | $5.11 | +945 | 285,698 | 0% | +$4,824 | |||||
| M | 2025-05-01 | CPIX | Cumberland Pharmaceuticals Inc | Jones James | Dir | P - Purchase | $5.11 | +168 | 43,168 | 0% | +$858 | |||||
| M | 2025-05-01 | CPIX | Cumberland Pharmaceuticals Inc | Young Caroline | Dir | P - Purchase | $5.11 | +84 | 32,569 | 0% | +$429 | |||||
| M | 2025-05-01 | CPIX | Cumberland Pharmaceuticals Inc | Kazimi A J | COB, CEO, 10% | P - Purchase | $5.11 | +168 | 5,699,260 | 0% | +$858 | |||||
| A | 2025-06-03 | KALA | Kala Bio, Inc. | Iwicki Mark T | Dir | S - Sale | $3.74 | -10,866 | 269,210 | -4% | -$40,639 | |||||
2025-06-03 | SXTP | 60 Degrees Pharmaceuticals, Inc. | Xu Cheryl | Dir | P - Purchase | $2.88 | +5,000 | 15,816 | +46% | +$14,410 | ||||||
| AD | 2025-03-26 | NTHI | Neonc Technologies Holdings, Inc. | Chiang Ming-Fu (Alan) | Dir | S - Sale+OE | $24.85 | -57,696 | 2,180,049 | -3% | -$1,433,912 | |||||
| AD | 2025-03-26 | NTHI | Neonc Technologies Holdings, Inc. | Walters Patrick | COO | S - Sale+OE | $24.85 | -11,847 | 876,373 | -1% | -$294,432 | |||||
| AD | 2025-03-26 | NTHI | Neonc Technologies Holdings, Inc. | Garnett Keithly | CFO | S - Sale+OE | $24.85 | -6,616 | 321,284 | -2% | -$164,426 | |||||
| AD | 2025-03-26 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | Dir | S - Sale+OE | $24.85 | -38,464 | 6,802,224 | -1% | -$955,941 | |||||
| AD | 2025-03-26 | NTHI | Neonc Technologies Holdings, Inc. | Chen Thomas C | CEO, 10% | S - Sale+OE | $24.85 | -39,233 | 4,843,191 | -1% | -$975,055 | |||||
2025-06-04 | ACAD | Acadia Pharmaceuticals Inc | Brege Laura | Dir | S - Sale | $21.78 | -14,446 | 15,095 | -49% | -$314,634 | ||||||
2025-06-04 | PCRX | Pacira Biosciences, Inc. | Riker Lauren | SVP, Finance | S - Sale | $26.21 | -5,578 | 59,564 | -9% | -$146,208 | ||||||
2025-06-04 | PCRX | Pacira Biosciences, Inc. | Williams Kristen | Chief Administrative Officer | S - Sale | $26.24 | -14,376 | 161,574 | -8% | -$377,226 | ||||||
| M | 2025-06-03 | ETON | Eton Pharmaceuticals, Inc. | Brynjelsen Sean | Pres, CEO, 10% | S - Sale | $17.11 | -210,000 | 2,873,513 | -7% | -$3,592,611 | |||||
| D | 2025-06-03 | TEVA | Teva Pharmaceutical Industries Ltd | Shields Matthew | EVP, Global Operations | S - Sale+OE | $17.02 | -6,206 | 9,989 | -38% | -$105,628 | |||||
2025-06-03 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $20.03 | -7,500 | 977,688 | -1% | -$150,220 | ||||||
2025-06-03 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Pres, CEO | S - Sale | $20.05 | -7,500 | 965,392 | -1% | -$150,352 | ||||||
| D | 2025-06-03 | KNSA | Kiniksa Pharmaceuticals International, Plc | Megna Michael R | CHIEF ACCOUNTING OFFICER | S - Sale+OE | $28.75 | -15,211 | 32,546 | -32% | -$437,316 | |||||
| D | 2025-06-03 | KNSA | Kiniksa Pharmaceuticals International, Plc | Moat Ross | CHIEF COMMERCIAL OFFICER | S - Sale+OE | $29.02 | -27,594 | 9,415 | -75% | -$800,778 | |||||
2025-06-05 | CYTK | Cytokinetics Inc | Kaye Edward M. Md | Dir | S - Sale | $32.10 | -3,636 | 29,658 | -11% | -$116,716 | ||||||
| D | 2025-06-03 | MAIA | Maia Biotechnology, Inc. | Smith Stan | Dir | P - Purchase | $1.50 | +33,333 | 1,305,059 | +3% | +$50,000 | |||||
| D | 2025-06-03 | KNSA | Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | CFO | S - Sale+OE | $28.80 | -18,299 | 27,009 | -40% | -$527,011 | |||||
2025-06-05 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale | $32.04 | -8,659 | 52,028 | -14% | -$277,434 | ||||||
2025-06-04 | AKBA | Akebia Therapeutics, Inc. | Malabre Richard C | SVP, Chief Accounting Officer | S - Sale | $3.53 | -13,334 | 266,914 | -5% | -$47,069 | ||||||
2025-06-03 | BPMC | Blueprint Medicines Corp | Carter Percy H. | Chief Scientific Officer | S - Sale | $127.88 | -2,659 | 54,206 | -5% | -$340,033 | ||||||
| D | 2025-06-04 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale+OE | $16.97 | -8,460 | 596,554 | -1% | -$143,566 | |||||
| D | 2025-06-04 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $16.97 | -6,656 | 224,921 | -3% | -$112,952 | |||||
| D | 2025-06-04 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale+OE | $16.97 | -7,597 | 273,209 | -3% | -$128,921 | |||||
| D | 2025-06-04 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale+OE | $16.97 | -30,610 | 2,633,241 | -1% | -$519,452 | |||||
| D | 2025-06-04 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $16.97 | -14,777 | 412,164 | -3% | -$250,766 | |||||
| D | 2025-06-03 | RYTM | Rhythm Pharmaceuticals, Inc. | McGirr David W J | Dir | S - Sale+OE | $65.22 | -65,431 | 3,000 | -96% | -$4,267,494 | |||||
| D | 2025-06-03 | RYTM | Rhythm Pharmaceuticals, Inc. | Meeker David P | Pres, CEO | S - Sale+OE | $65.05 | -43,620 | 201,825 | -18% | -$2,837,333 | |||||
| D | 2025-06-04 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $16.97 | -3,597 | 193,735 | -2% | -$61,041 | |||||
| M | 2025-06-04 | IMUX | Immunic, Inc. | Neermann Joerg | Dir | P - Purchase | $0.77 | +100,000 | 200,000 | +100% | +$76,700 | |||||
| M | 2025-06-03 | HROW | Harrow, Inc. | Opaleye Management Inc. | 10% | S - Sale | $30.03 | -4,796 | 3,935,204 | 0% | -$144,024 | |||||
2025-06-04 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $2.85 | +10,000 | 569,925 | +2% | +$28,500 | ||||||
| DM | 2025-06-02 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $11.15 | -1,000,000 | 1,462,223 | -41% | -$11,154,942 | |||||
2025-06-02 | CORT | Corcept Therapeutics Inc | Belanoff Joseph K | CEO | S - Sale | $82.86 | -40,000 | 2,901,985 | -1% | -$3,314,310 | ||||||
| D | 2025-06-02 | CORT | Corcept Therapeutics Inc | Lyon Joseph Douglas | See Remarks | S - Sale+OE | $78.04 | -5,000 | 10,066 | -33% | -$390,218 | |||||
| D | 2025-06-02 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $79.08 | -20,000 | 117,398 | -15% | -$1,581,686 | |||||
| M | 2025-06-02 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $10.02 | -8,216 | 25,782 | -24% | -$82,342 | |||||
2025-06-03 | KALA | Kala Bio, Inc. | Kharabi Darius | CHIEF BUSINESS OFFICER | S - Sale | $3.74 | -730 | 67,077 | -1% | -$2,730 | ||||||
2025-06-03 | KALA | Kala Bio, Inc. | Reumuth Mary | CFO | S - Sale | $3.74 | -2,850 | 65,731 | -4% | -$10,659 | ||||||
2025-06-03 | KALA | Kala Bio, Inc. | Bazemore Todd | SEE REMARKS | S - Sale | $3.74 | -3,390 | 87,758 | -4% | -$12,679 | ||||||
2025-06-03 | KALA | Kala Bio, Inc. | Brazzell Romulus K | SEE REMARKS | S - Sale | $3.74 | -3,687 | 87,949 | -4% | -$13,789 | ||||||
2025-06-03 | KALA | Kala Bio, Inc. | Iwicki Mark T | Dir | S - Sale | $3.74 | -10,866 | 269,210 | -4% | -$40,639 | ||||||
| D | 2025-06-02 | AMPH | Amphastar Pharmaceuticals, Inc. | Petersen Floyd F. | Dir | S - Sale+OE | $25.67 | -500 | 78,031 | -1% | -$12,835 | |||||
2025-06-02 | TBPH | Theravance Biopharma, Inc. | Farnum Rhonda | SVP, COMM, MEDICAL AFFAIRS | S - Sale | $11.00 | -24,000 | 336,918 | -7% | -$264,000 | ||||||
2025-06-03 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale | $71.50 | -1,448 | 69,597 | -2% | -$103,532 | ||||||
2025-06-03 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale | $71.50 | -1,686 | 83,111 | -2% | -$120,549 | ||||||
2025-06-03 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale | $71.50 | -1,860 | 141,323 | -1% | -$132,990 | ||||||
2025-06-03 | INSM | Insmed Inc | Bonstein Sara | CFO | S - Sale | $71.50 | -1,579 | 113,288 | -1% | -$112,899 | ||||||
| D | 2025-06-02 | AKRO | Akero Therapeutics, Inc. | Lamy Patrick | SVP, Commercial Strategy | S - Sale+OE | $50.31 | -4,000 | 33,492 | -11% | -$201,258 | |||||
2025-06-03 | RGLS | Regulus Therapeutics Inc. | Klassen Preston | Pres, Head of R, D | P - Purchase | $7.99 | +12,000 | 48,055 | +33% | +$95,852 | ||||||
| M | 2025-06-02 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | COB, CEO | S - Sale | $108.95 | -1,000 | 437,973 | 0% | -$108,950 | |||||
| D | 2025-06-02 | RNA | Avidity Biosciences, Inc. | Gallagher Kathleen P. | Chief Program Officer | S - Sale+OE | $32.48 | -5,875 | 50,554 | -10% | -$190,833 | |||||
2025-06-03 | INSM | Insmed Inc | Schaeffer Orlov S Nicole | Chief People Strategy Officer | S - Sale | $71.50 | -1,642 | 118,579 | -1% | -$117,403 | ||||||
| M | 2025-06-03 | INSM | Insmed Inc | McGirr David W J | Dir | S - Sale | $72.25 | -6,250 | 97,723 | -6% | -$451,535 | |||||
| DM | 2025-06-02 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $71.39 | -12,302 | 593,182 | -2% | -$878,292 | |||||
2025-06-02 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale | $30.00 | -9,618 | 17,429 | -36% | -$288,540 | ||||||
2025-06-03 | ZTS | Zoetis Inc. | Lagano Roxanne | EVP | S - Sale | $170.00 | -652 | 15,943 | -4% | -$110,840 | ||||||
2025-06-03 | IMUX | Immunic, Inc. | Whaley Glenn | CFO | P - Purchase | $0.71 | +45,000 | 95,510 | +89% | +$32,076 | ||||||
| DM | 2025-06-02 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Dir | S - Sale+OE | $46.06 | -8,203 | 0 | -100% | -$377,843 | |||||
2025-06-03 | IMUX | Immunic, Inc. | Rudick Richard Alan | Dir | P - Purchase | $0.70 | +143,075 | 230,375 | +164% | +$100,024 | ||||||
| M | 2025-06-02 | VREO | Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% | P - Purchase | $0.40 | +182,700 | 111,200,655 | 0% | +$72,962 | |||||
2025-06-04 | MTVA | Metavia Inc. | Woodworth Marshall H | CFO | P - Purchase | $0.70 | +14,200 | 44,279 | +47% | +$9,940 | ||||||
2025-06-04 | CLNN | Clene Inc. | General Resonance LLC | 10% | S - Sale | $4.04 | -600 | 707,992 | 0% | -$2,424 | ||||||
2025-06-03 | IMNM | Immunome Inc. | Bienaime Jean Jacques | Dir | P - Purchase | $9.38 | +5,000 | 36,415 | +16% | +$46,900 | ||||||
| D | 2025-05-29 | CKPT | Checkpoint Therapeutics, Inc. | Fortress Biotech, Inc. | 10% | S - Sale+OE | $1.29 | -100,000 | 0 | -100% | -$129,000 | |||||
2025-05-30 | CALC | Calcimedica, Inc. | Bardin Stephen | CFO | P - Purchase | $1.69 | +1,000 | 41,000 | +3% | +$1,690 | ||||||
2025-05-30 | CPRX | Catalyst Pharmaceuticals, Inc. | Daly Richard J | Pres, CEO | S - Sale | $24.86 | -70,000 | 199,764 | -26% | -$1,740,200 | ||||||
| D | 2025-06-02 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale+OE | $16.74 | -923 | 586,222 | 0% | -$15,451 | |||||
| D | 2025-06-02 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $16.74 | -581 | 216,038 | 0% | -$9,726 | |||||
2025-06-02 | ANTX | An2 Therapeutics, Inc. | Easom Eric | CEO | P - Purchase | $1.07 | +10,000 | 1,516,262 | +1% | +$10,665 | ||||||
| D | 2025-06-02 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $16.74 | -859 | 397,800 | 0% | -$14,380 | |||||
| D | 2025-06-02 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $16.74 | -451 | 184,961 | 0% | -$7,550 | |||||
| D | 2025-06-02 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $325.82 | -12,000 | 8,118 | -60% | -$3,909,893 | |||||
| D | 2025-06-03 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $31.88 | -2,000 | 140,610 | -1% | -$63,760 | |||||
2025-06-02 | OCUL | Ocular Therapeutix, Inc | Waheed Nadia | Chief Medical Officer | S - Sale | $8.05 | -13,861 | 206,805 | -6% | -$111,581 | ||||||
| D | 2025-05-30 | RYTM | Rhythm Pharmaceuticals, Inc. | Smith Hunter C | CFO | S - Sale+OE | $61.41 | -23,400 | 109,929 | -18% | -$1,437,010 | |||||
| DM | 2025-05-30 | ALNY | Alnylam Pharmaceuticals, Inc. | Greenstreet Yvonne | CEO | S - Sale+OE | $305.00 | -50,937 | 49,355 | -51% | -$15,535,784 | |||||
2025-05-30 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale | $69.65 | -26,327 | 71,045 | -27% | -$1,833,779 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |